ClinicalTrials.gg
CompletedNCT05108051Updated Nov 4, 2021

Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir

A Phase 1 interventional study of ZSP1273 and Oseltamivir in Drug-drug Interaction, sponsored by Guangdong Raynovent Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-04.

Sponsored by Guangdong Raynovent Biotech Co., Ltd (part of Guangdong Zhongsheng Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Nov 2020, registered Sep 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To evaluate the drug-drug interaction between ZSP1273 and oseltamivir, the pharmacokinetic characteristics and safety of ZSP1273 and oseltamivir in healthy subjects, so as to provide a basis for the design of administration regimen in subsequent clinical trials.

02

Conditions studied

  • Drug-drug Interaction
03

In context

Lead sponsor

Guangdong Raynovent Biotech Co., Ltd is the lead sponsor of 36 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and female subjects between 18-45 years (Both inclusive);
  • Body weight is no less than 50kg in males and no less than 45kg in females. (BMI) 18\~26 kg/m2 (Both inclusive); BMI is determined by the following equation: BMI = weight/height2 (kg/m2);
  • Subjects (including partners) are willing to voluntarily use effective from screening to 3 months after the last study drug administration.

Exclusion criteria

Exclusion Criteria:

  • Known history of allergic constitution (multiple drugs especially with ZSP1273 or oseltamivir and its preparation of the main ingredient allergy, food allergy);
  • Subjects who donated blood or bleeding profusely(> 450 mL)in the 3 months preceding study screening;
  • History or presence of any disease or condition known to increase the risk of bleeding, eg.hemorrhoids, acute gastritis or gastric and duodenal ulcer, etc;
  • Use of any prescription or over-the-counter (OTC) medications, vitamins and herbal within 14 days prior to screening;
  • Concomitant therapy with any drugs with known hepatic enzyme-inducing or inhibiting agents that may change the activity of drug metabolic enzymes ,is intended to be taken in combination 28 days prior to screening or during the study period;
  • Participated in another clinical research study or received any products within 3 months prior to dosing;
  • Presence of abnormalities in , >450ms in males,or QTcB>470ms in females;
  • Any of the following diseases (including but not limited to gastrointestinal, renal, liver, neurological, hematological, endocrine, tumor, pulmonary, immune, psychiatric or cardiovascular and cerebrovascular diseases) that are clinically significant in clinical laboratory examination or other clinical findings within 6 months prior to screening;
  • Breast-feeding women or those with positive pregnancy test results;
  • Subjects who should not be included in the study in the opinion of the Investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    sequence 1

    Period 1: study of ZSP1273's pharmacokinetics at steady state; Period 2: study of Oseltamivir's pharmacokineticsat at steady state; Period 3: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state.

    Drug: ZSP1273 · Drug: Oseltamivir

  • Experimental
    sequence 2

    Period 1: study of Oseltamivir's pharmacokineticsat at steady state; Period 2: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state; Period 3: study of ZSP1273's pharmacokinetics at steady state.

    Drug: ZSP1273 · Drug: Oseltamivir

  • Experimental
    sequence 3

    Period 1: study of ZSP1273's pharmacokinetics under Oseltamivir at steady state; Period 2: study of ZSP1273's pharmacokinetics at steady state; Period 3: study of Oseltamivir's pharmacokineticsat at steady state.

    Drug: ZSP1273 · Drug: Oseltamivir

Interventions

  • ZSP1273 tablets 600mg administered orally once daily

  • Oseltamivir 75mg administered orally twice daily

06

What researchers measure

Primary outcomes

  1. Plasma pharmacokinetics

    Tmax

    Time frame: pre-dose and up to 72hours post-dose

  2. Plasma pharmacokinetics

    t1/2

    Time frame: pre-dose and up to 72hours post-dose

  3. Plasma pharmacokinetics

    Cmax

    Time frame: pre-dose and up to 72hours post-dose

  4. Plasma pharmacokinetics

    AUC0-∞

    Time frame: pre-dose and up to 72hours post-dose

  5. Plasma pharmacokinetics

    CL/F

    Time frame: pre-dose and up to 72hours post-dose

  6. Number of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE)

    TEAEs will be summarized displaying the number of TEAEs along with the number and percentage of participants with at least one TEAE according to: Number of AEs, Severity and relation to study drug.

    Time frame: up to 37days

07

Study locations

1 site
  • Guangdong Provincial Hospital of Chinese Medicine
    Guangzhou, Guangdong 510000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Mar 2021, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2021
First posted
Nov 4, 2021
StartActual
Nov 19, 2020
Primary completionActual
Mar 17, 2021
CompletionActual
Mar 17, 2021
Last update
Nov 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05108051
Responsible party
Sponsor
First posted
Nov 4, 2021
Start date
Nov 19, 2020
Primary completion
Mar 17, 2021
Completion
Mar 17, 2021
Last update
Nov 4, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ZSP1273 · Oseltamivir

Start the discussion